MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Kinase"

  • 2023 International Congress

    Analysis of the therapeutic potential of c-Abl inhibition in Multiple System Atrophy

    M. Werner, E. Bertin, A. Simmonet, E. Noé, P. Fernagut, J. Molina, K. Lowe, E. Bezard, J. Kordower (Atlanta, USA)

    Objective: IkT-148009 is a potent selective inhibitor of non-receptor Abelson Tyrosine Kinases (c-Abl kinases).  Our recent analysis of post-mortem brain tissue from patients with Multiple…
  • 2023 International Congress

    Analysis of the therapeutic potential of IkT-148009 in Parkinson’s disease

    M. Werner, R. Rush, T. Kelly, S. Singh, S. Kruger, C. Olanow, A. Mcgarry (Atlanta, USA)

    Objective: To evaluate the therapeutic potential of the selective, brain penetrant c-Abl inhibitor IkT-148009 in mouse models of progressive PD and the safety and tolerability…
  • 2022 International Congress

    Neuroprotective effects of Ibudilast, a Phosphodiesterase IV inhibitor in mouse model of Parkinson’s disease

    M. Sarswati, A. Gaur (Delhi, India)

    Objective: In the present study, we examined neuroprotective effects, if any, of IBD drug, a  inhibitor of the phosphodiesterase IV in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse…
  • MDS Virtual Congress 2020

    Blood hexokinase reduction in de novo Parkinson’s disease and remodeling of glycolytic energy homeostasis with L-DOPA/Istradefylline combination therapy

    N. Kanzato, K. Nakachi, S. Mochizuki, (Okinawa, Japan)

    Objective: To evaluate the glycolytic energy homeostasis in Parkinson’s disease (PD), and to define the effects of PD pharmacotherapies on glycolytic dynamics Background: Neuronal energy…
  • 2019 International Congress

    Differential enhancement of ERK, PKA and Ca2+ signaling in direct and indirect striatal neurons of Parkinsonian mice

    LL. Mariani, S. Longueville, JA. Girault, D. Hervé, N. Gervasi (Paris, France)

    Objective: To identify cell-specific and dynamical modifications of signaling pathways associated with PD and drug-induced modifications Background: Parkinson's disease (PD) is characterized by severe locomotor…
  • 2019 International Congress

    Case report: Chorea-acynthocytosis with two compoud heterozygous VPS13A large deletions

    D. Spieler, A. Mühlbäck, A. Velayos-Baeza, F. Castrop, C. Maegerlein, J. Slotta-Hispenina, B. Bader, B. Haslinger, J. Klempir, A. Danek (Freiburg, Germany)

    Objective: We report a 33 year old male patient without functional protein due to compound heterozygosity for VPS13A deletions and discuss the molecular diagnostic difficulties…
  • 2019 International Congress

    K0706, A Potent Orally Bioavailable Brain-Penetrating Selective Inhibitor of cABL Protein Tyrosine Kinase, Exhibits Neuroprotective Activity in Preclinical Models of Parkinson’s Disease

    S. Mandhane, D. Soni, K. Jani, P. Sengupta, A. Patel, R. Bambal, V. Ramanathan, Y. Zala, N. Dharmadhikari, C. Rao, A. Raghavan, N. Damle (Vadodara, India)

    Objective: Preclinical assessment of K0706, a potent c-Abl inhibitor, as a neuroprotective disease modifying agent for the treatment of Parkinson’s disease (PD) related neurodegeneration using…
  • 2018 International Congress

    Abnormal signaling along the non-canonical molecular cascade GRK6/β-arrestin2/Akt/GSK-3β in the putamen is associated with tardive dyskinesia following chronic haloperidol exposure in a primate model

    P. Blanchet, G. Hernandez, S. Mahmoudi, M. Cyr, J. Diaz, D. Levesque (Montreal, QC, Canada)

    Objective: To investigate the neurochemical basis of tardive dyskinesia (TD) in an experimental primate model. Background: TD is a potentially irreversible motor complication occurring in…
  • 2018 International Congress

    Intrastriatal Fyn silencing as a gene therapy strategy to manage levodopa induced dyskinesia in a mice model of Parkinson’s disease

    M. Bordone, A. Damianich, A. Bernardi, E. Avale, O. Gershanik, J. Ferrario (CABA, Argentina)

    Objective: To genetically abrogate Fyn expression to reduce levodopa induced dyskinesia (LID) in the 6-OHDA mice model of Parkinson’s disease (PD), using intrastriatal-injected lentiviral (LV)…
  • 2018 International Congress

    Novel mechanistic involved in targeting Parkinsons Disease by Indolocarbazole derivatives as inhibitors against Cyclin Dependent kinases using molecular modelling and simulation approaches

    S. Iqbal (Chennai, India)

    Objective: To validate effect of Indolocarbazole derivatives on Cyclin dependent kinase for treating Parkinson's (Preliminary work in context of CDK5 assay and Simulations have been…
  • 1
  • 2
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Welcome to the MDS Abstracts Site
  • Patients with Essential Tremor Live Longer than their Relatives
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Advanced Search
  • To be or not to bupropion: a drug-induced parkinsonism?
  • Welcome to the MDS Abstracts Site
  • Advanced Search
  • #23972 (not found)
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Patients with Essential Tremor Live Longer than their Relatives
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Insulin dependent diabetes and hand tremor
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2023 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley